Simon J. Harrison, MD, gives key takeaways from his presentation on the ICARIA-MM study, which he recently presented at the 2019 International Myeloma Workshop.<br />
Videos
Paul G. Richardson, MD, clinical program leader and director of clinical research of the Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute and RJ Corman Professor of Medicine, Harvard School of Medicine, discusses the interesting safety and efficacy profiles of the HORIZON trial.
Prithviraj Bose, MD, discusses differences in the safety profiles of ruxolitinib and fedratinib in the treatment of myelofibrosis.
Kazuhiko Nakagawa, MD, PhD, discusses the role of EGFR tyrosine kinase inhibitors for the frontline treatment of patients with <em>EGFR</em>-positive non–small cell lung cancer.
Graft versus Host Disease
David S. Snyder, MD, discusses using ruxolitinib to prevent patients receiving stem cell transplantation from developing graft versus host disease.
Sarah Ferguson, MD, FRCSC, discusses her experience being involved in a population-based study of women with cervical cancer treated with a radical hysterectomy.
Kim N. Chi, MD, discusses the safety findings for the next-generation androgen receptor inhibitor apalutamide in combination with androgen deprivation therapy in patients with metastatic castration-sensitive prostate cancer, according to findings from the phase III TITAN study. This combination was compared with placebo and ADT and presented at the 2019 ASCO Annual Meeting.
Aditya Bardia, MBBS, MPH, discusses the value of liquid biopsies in the treatment landscape of breast cancer. The real value of liquid biopsy in this space lies in providing oncologists with insight on what’s happening in tumor evolution.
Optimal Management of Relapsed/Refractory mHCC
Sagar Lonial, MD, discusses how phase III trials should be designed in the United States for patients with multiple myeloma in the early-relapse setting.
Jesus Anampa, MD, MS, assistant professor, Department of Medicine, Albert Einstein School of Medicine, says in the past, most patients with breast cancer were treated with chemotherapy. In some cases, these patients were being over-treated. To limit the use of chemotherapy in patients who don’t need it, a group of researchers conducted the TAILORx trial.
Keith T. Flaherty, MD, discusses the combination regimens and the potential role for a 3-drug regimen as treatment for patients with melanoma. He says investigators have been searching for new combination strategies beyond the combination of BRAF and MEK inhibitors.
Jorge E. Cortes, MD, discusses the frontline treatment options for patients with chronic myeloid leukemia.
Angela DeMichele, MD, MSCE, discusses predictors of response to neoadjuvant chemotherapy in various subgroups of patients with breast cancer. Selecting characteristics of patients who will most likely benefit from this therapy is not an exact science, she adds.
Sarah B. Goldberg, MD, MPH, discusses the role of clinical trials in patients with lung cancer who have molecularly altered tumors, such as <em>EGFR</em>, <em>ALK</em>, <em>BRAF</em>,<em>ROS1, </em>or other alterations. These patients typically consider either targeted therapy or immunotherapy treatment options.
